Browse by Medical Category
Accepting New Patients
Currently, Dr.Chen divides his time between patient care and clinical research with a focus on patients undergoing bone marrow/stem cell transplantation. He invites you to contact him directly with any questions. New patients please call 617-724-6587
Go To Programs
Go To Programs
Go To Specialties
Yi-Bin Chen grew up in New Jersey. He majored in molecular biology, earning a B.S./M.S. at Yale University before attending medical school at Harvard Medical School. Subsequently, he did his internship and residency at Massachusetts General Hospital including an additional year as Chief Resident. This was followed by a fellowship in hematology / oncology at the Dana-Farber Partners combined program. In 2008, he joined the staff of the Bone Marrow Transplant Unit at the MGH Cancer Center. His interests mainly revolve around clinical care of patients underoing autologous and allogeneic stem cell transplant. In addition, he serves as Director oc Clinical Research for the BMT program at MGH, directing an active portfolio of clinical trials aimed to improve outcomes for patients undergoing stem cell transplantation. He collaborates extensively with local and national colleagues as well as industry in addition to developing his own original clinical trials. He currently lives in Needham, MA with his wife and 2 children.
Chen YB, Li S, Lane AA, et al. ?Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for FLT3-ITD AML.? Biol Blood Marrow Transplant. 2014, 20(12):2042-8.
Chen, YB, McDonough S, Hasserjian R, et al. "Expression of CD30 in Patients with Acute Graft-vs.-Host Disease." Blood 2012; 120(3):691-6.
Chen YB, Kim H, McDonough S, et al."Upregulation of a4b7 integrin on peripheral blood memory T-cells predicts for intestinal graft-versus-host disease (GVHD) following allogeneic stem cell transplantation." Biol of Blood and Marrow Transplant. 2009;15:1066-76.
Chen YB and Spitzer TR. "Current status of reduced intensity transplantation using alternative donors." Leukemia. 2008;22:31-41.
Back to Top